1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N
Engl J Med 333: 1540-1545, 1995.
2. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with
autologous transplantation for relapsed large B-cell lymphoma in
the rituximab era. J Clin Oncol 28: 4184-4190, 2010.
3. Kameoka Y, Takahashi N, Ishizawa K, et al. Safety and feasibility
of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem
cell transplantation for malignant lymphoma. Int J Hematol 96:
624-630, 2012.
4. Weisdorf SA, Lysne J, Wind D, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow
transplantation. Transplantation 43: 833-838, 1987.
5. Ekelund M, Kristensson E, Ekelund M, Ekblad E. Total parenteral
nutrition causes circumferential intestinal atrophy, remodeling of
the intestinal wall, and redistribution of eosinophils in the rat gastrointestinal tract. Dig Dis Sci 52: 1833-1839, 2007.
6. Hernandez G, Velasco N, Wainstein C, et al. Gut mucosal atrophy
after a short enteral fasting period in critically ill patients. J Crit
Care 14: 73-77, 1999.
7. Alverdy JC, Aoys E, Moss GS. Total parenteral nutrition promotes
bacterial translocation from the gut. Surgery 104: 185-190, 1988.
8. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 39:
237-238, 1998.
9. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus
GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 104: e64, 1999.
10. Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe
DM. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 6: 1449-1454, 2007.
11. Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal
cancer: a randomised study. Br J Cancer 97: 1028-1034, 2007.
12. Colombel JF, Cortot A, Neut C, Romond C. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal
effects. Lancet 2: 43, 1987.
13. Suvorov A. Gut microbiota, probiotics, and human health. Biosci
Microbiota Food Health 32: 81-91, 2013.
14. Gibson GR, Roberfroid MB. Dietary modulation of the human
colonic microbiota: introducing the concept of prebiotics. J Nutr
125: 1401-1412, 1995.
15. Takagi T, Naito Y, Higashimura Y, et al. Partially hydrolysed guar
gum ameliorates murine intestinal inflammation in association
with modulating luminal microbiota and SCFA. Br J Nutr 116:
1199-1205, 2016.
16. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics
- approaching a definition. Am J Clin Nutr 73: 361s-364s, 2001.
17. Motoori M, Yano M, Miyata H, et al. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse
events in esophageal cancer patients. Clin Nutr 36: 93-99, 2017.
18. Iyama S, Sato T, Tatsumi H, et al. Efficacy of enteral supplementation enriched with glutamine, fiber, and oligosaccharide on mucosal injury following hematopoietic stem cell transplantation.
Case Rep Oncol 7: 692-699, 2014.
19. Miyoshi M, Kadoguchi H, Usami M, Hori Y. Synbiotics improved
stool form via changes in the microbiota and short-chain fatty acids in hemodialysis patients. Kobe J Med Sci 67: E112-E118,
2021.
20. Harris JA, Benedict FG. A biometric study of human basal metabolism. Proc Natl Acad Sci U S A 4: 370-373, 1918.
21. O’Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea
by simple clinical assessment of intestinal transit rate. BMJ 300:
439-440, 1990.
22. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a
quality-of-life instrument for use in international clinical trials in
oncology. J Natl Cancer Inst 85: 365-376, 1993.
23. Russo F, Linsalata M, Clemente C, et al. Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels
of zonulin and glucagon-like peptide 2 in healthy young volunteers. Nutr Res 32: 940-946, 2012.
24. Kanda Y. Investigation of the freely available easy-to-use software
‘EZR’ for medical statistics. Bone Marrow Transplant 48: 452458, 2013.
25. van Kraaij MG, Dekker AW, Verdonck LF, et al. Infectious gastroenteritis: an uncommon cause of diarrhoea in adult allogeneic and
autologous stem cell transplant recipients. Bone Marrow Transplant 26: 299-303, 2000.
26. Pala C, Kaynar L, Buyukoglan R, et al. Diarrhea in peripheral
stem cell transplant recipients: a developing country’s experience.
J Infect Dev Ctries 8: 635-641, 2014.
27. Ciernikova S, Kasperova B, Drgona L, Smolkova B, Stevurkova V,
Mego M. Targeting the gut microbiome: an emerging trend in hematopoietic stem cell transplantation. Blood Rev 48: 100790,
2021.
2957
Intern Med 62: 2949-2958, 2023
DOI: 10.2169/internalmedicine.1314-22
28. Redman MG, Ward EJ, Phillips RS. The efficacy and safety of
probiotics in people with cancer: a systematic review. Ann Oncol
25: 1919-1929, 2014.
29. Muscaritoli M, Grieco G, Capria S, Iori AP, Rossi Fanelli F. Nutritional and metabolic support in patients undergoing bone marrow transplantation. Am J Clin Nutr 75: 183-190, 2002.
30. Fuji S, Kim SW, Mori S, et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation 84: 814-820, 2007.
31. Fuji S, Mori T, Khattry N, et al. Severe weight loss in 3 months
after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality. Bone Marrow
Transplant 50: 100-105, 2015.
32. Fuji S, Kim SW, Fukuda T, Kamiya S, Kuwahara S, Takaue Y.
Positive impact of maintaining minimal caloric intake above 1.0 ×
basal energy expenditure on the nutritional status of patients undergoing allogeneic hematopoietic stem cell transplantation. Am J
Hematol 84: 63-64, 2009.
33. Heidegger CP, Berger MM, Graf S, et al. Optimisation of energy
provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet 381: 385-393,
2013.
34. Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol
76: 561-583, 2014.
35. Norona J, Apostolova P, Schmidt D, et al. Glucagon-like peptide 2
36.
37.
38.
39.
40.
41.
for intestinal stem cell and Paneth cell repair during graft-versushost disease in mice and humans. Blood 136: 1442-1455, 2020.
Tappenden KA, Albin DM, Bartholome AL, Mangian HF.
Glucagon-like peptide-2 and short-chain fatty acids: a new twist to
an old story. J Nutr 133: 3717-3720, 2003.
Sugahara H, Odamaki T, Fukuda S, et al. Probiotic Bifidobacterium longum alters gut luminal metabolism through modification
of the gut microbial community. Sci Rep 5: 13548, 2015.
Reider SJ, Moosmang S, Tragust J, et al. Prebiotic effects of partially hydrolyzed guar gum on the composition and function of the
human microbiota - results from the PAGODA Trial. Nutrients 12:
1257, 2020.
Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiomederived metabolites modulate intestinal epithelial cell damage and
mitigate graft-versus-host disease. Nat Immunol 17: 505-513,
2016.
Elting LS, Chang YC. Costs of oral complications of cancer therapies: estimates and a blueprint for future study. J Natl Cancer Inst
Monogr 2019: lgz010, 2019.
Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin
on the costs of hospitalization for autologous hematopoietic stemcell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 13: 806-813, 2007.
The Internal Medicine is an Open Access journal distributed under the Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To
view the details of this license, please visit (https://creativecommons.org/licenses/
by-nc-nd/4.0/).
Ⓒ 2023 The Japanese Society of Internal Medicine
Intern Med 62: 2949-2958, 2023
2958
...
論文の公開元へ
